Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70096 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Impact of Ex Vivo Lung Perfusion on Inpatient Cost: A Propensity Score‐Matched Analysis of the US Nationwide Healthcare Cost and Utilization Project Database Victoria Yin Scott M. Atay John C. S. Rodman Sean C. Wightman Graeme M. Rosenberg Brooks V. Udelsman Anthony W. Kim Takashi Harano Clinical Transplantation ABSTRACTBackgroundThe goal of this study was to investigate the association between ex vivo lung perfusion (EVLP) use and inpatient hospitalization cost for lung transplantation in a nationwide sample.MethodsLung transplantation patients in 2018–2020 Nationwide Readmissions Database (NRD) were grouped based on use of EVLP. The primary outcome was total inpatient hospitalization cost. 1:2 propensity score matching by EVLP status was performed followed by multivariable linear regression to determine the association between inpatient cost and EVLP while adjusting for pre‐transplant hospital days, high volume EVLP center status, and propensity score.ResultsThere were 3902 lung transplants and 118 (3%) were recipients of EVLP lungs. Among EVLP patients, the median cost was $871 468 (IQR: $608 671–1 274 392), compared to $846 516 (IQR: $531 462–1 439 267, p = 0.871) among the total non‐EVLP cohort. After 1:2 propensity score‐matched cohort, recipients of EVLP lungs had longer median hospital length of stay (p = 0.046). In the multivariable model using the matched sample, increased cost was not associated with EVLP use (p = 0.783); however, high volume EVLP centers were associated with decreased cost (p = 0.018).ConclusionsEVLP use was not associated with greater inpatient costs and may be favorable at high volume centers. 10.1111/ctr.70096 http://onlinelibrary.wiley.com/termsAndConditions#vor